Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Methodology, version 4.1

Released: · Last reviewed:

Every commercial figure on this site lives in a public evidence ledger with a source, capture date, verification status, and confidence level. Affordability uses effective monthly cost — total mandatory cost divided by verified months of treatment supplied — including membership, provider, laboratory, onboarding, shipping, and dose-surcharge fees, and excluding coupons, referral credits, and financing effects. Advertised-price findings publish with full qualification; verified all-inclusive rankings publish only when at least three eligible programs per category hold current Verified evidence.

Purpose

This methodology exists to make every conclusion on the site reproducible: given the same evidence records, a reader should reach the same numbers and the same qualified findings. It governs what gets captured, how prices are normalized, when a claim may publish, how conflicts and staleness are handled, and how commercial relationships are controlled. Where a rule here conflicts with making any provider look good, the rule wins.

Scope

The methodology covers compounded semaglutide and compounded tirzepatide programs sold by U.S. telehealth providers, in injectable, ODT, sublingual, and oral forms, across standard-dose and marketed "microdose" plans. Manufacturer and brand-access channels (LillyDirect, NovoCare, Amazon Pharmacy, savings-card and insurance pathways) are profiled as a separate class and are never ranked against compounded programs. Clinical-evidence pages follow the research-review rules summarized here and detailed on each research page. Nothing in scope constitutes medical, legal, or financial advice.

Definitions

Advertised price is the price a provider displays publicly for a plan before checkout, captured with date and source. Effective monthly cost is total mandatory cost for the treatment period divided by verified months of treatment supplied. Mandatory cost includes medication, required membership, required consultations, provider fees, laboratory fees, onboarding fees, mandatory shipping, dose surcharges, required refill charges, required supplies, and any required advance payment.

First-month cost is everything required before or during month one, including one-time fees. Renewal cost is the recurring price after any introductory pricing ends. Commitment-adjusted cost presents the total contractual commitment, the amount due today, the number and frequency of payments, medication shipped per shipment, and treatment months represented.

Page vocabulary is fixed: "cheapest" pages analyze advertised or upfront price; "most affordable" pages analyze verified normalized all-inclusive cost; "best value" pages additionally weigh dose coverage, clinical support, pharmacy transparency, commitment, renewal pricing, cancellation terms, and evidence quality. The three are different questions and are never merged into one list.

Entities and identity

Records distinguish four identities that marketing usually blurs: the consumer-facing brand, the legal business entity behind it, the medical group employing or contracting the prescribing clinicians, and the dispensing pharmacy. A price belongs to a brand's program; a license belongs to a pharmacy or clinician; a lawsuit or warning letter belongs to a legal entity. Conclusions are attached to the correct identity, and where the corporate structure is undisclosed — common in telehealth — the gap is recorded as an evidence gap on the provider's page rather than papered over with the brand name.

Verification statuses and confidence

VERIFIED first-party checkout or document capture, archived. PROVIDER REPORTED taken from official provider pages, unconfirmed at checkout. CALCULATED arithmetic we performed from captured figures, shown to the cent. CONFLICTING sources disagree, or a claim contradicts itself — suppressed from rankings and flagged on-page. PENDING known entity, capture incomplete. Additional ledger statuses: Estimated, Not Publicly Disclosed, Stale, Historical, No Longer Current, Not Applicable. Confidence (High/Moderate/Low) reflects source quality and internal consistency, and is recorded per record, not per provider.

Comparison population

All cost conclusions are computed for a generally available cash-pay adult consumer in the United States: no insurance offsets, no employer subsidies, no eligibility-restricted savings cards, and no assumption of clinical suitability. This population choice is what makes figures comparable across providers — and it is also a limitation, because an individual reader with coverage, a subsidy, or a restrictive medical history will face different real numbers. Category pages restate this population so that no conclusion travels without it, and insured or subsidized pathways are analyzed on their own pages under their own assumptions rather than blended into cash-pay rankings.

Evidence standards

Sources are used in a fixed hierarchy: FDA, NIH, PubMed, ClinicalTrials.gov, CMS, state pharmacy and medical boards, court records, the Federal Register, official drug labels, peer-reviewed journals, manufacturer medical and pricing pages, official provider pages, checkout evidence, provider terms, official pharmacy pages, archived first-party captures, reputable news organizations, and secondary editorial sources — in that order. Another comparison or affiliate site is never the primary source for pricing, pharmacy status, availability, credentials, cancellation terms, FDA status, warning letters, or ownership. Authoritative identifiers (DOI, PMID, NCT, NPI, license, FEI, warning-letter and recall numbers) are stored when available and are never printed from memory.

Core inference rules: unknown never equals zero — unknown shipping is not free shipping, an unknown membership fee is not no fee, unknown availability is not nationwide, and an undisclosed pharmacy is not transparent disclosure. Provider Reported is not Verified. An archived price is not a current price. A starting dose is not an all-dose price; a starter offer is not renewal pricing; a coupon price is not generally available pricing. A monthly equivalent does not mean monthly billing, and a multi-month commitment does not mean monthly shipments. A 503B registration does not mean any product is approved. Evidence for an FDA-approved product does not automatically support a compounded formulation, and injectable evidence does not support ODT, sublingual, oral, or troche formulations.

Worked examples of the formula

Flat-rate program, longest plan: NexLife's standard semaglutide plan page (read November 6, 2026) prints $95 a month on the 12-month plan, with no membership and the same price at every dose, so twelve months = 12 × $95 = $1,140 and the all-in monthly figure is $95.00. Month-to-month it prints $109, so $109.00. The $14 gap is the price of not committing. NexLife's plan pages say longer plans "start only if you're prescribed" and that "unshipped months are refunded if treatment stops"; they do not say in one sentence whether the 12-month total is collected at checkout, so we do not describe it as either billed monthly or paid up front.

Annual-membership program: Collective prints compounded tirzepatide at $69 a month beside a $199 membership "billed annually—not monthly" (read October 15, 2026). All-in: $69 + $199 ÷ 12 = $69 + $16.58 = $85.58 a month. A program whose headline already includes everything shows no gap; a program with a fee outside the headline shows one, and the formula puts both on the same scale.

Rounding is display-only. Where a division isn't exact we publish the figure to the cent and label a provider's rounded number as provider-advertised. Numbers on this site are reproducible from their inputs, or they don't publish.

Why the exclusions are excluded

Coupons, influencer codes, and referral credits are excluded because they are not generally available: a comparison population can't reliably obtain them, so including them makes the ranked price a lottery ticket. FSA/HSA advantages are excluded because they depend on individual tax situations, not the program. Conditional rebates and hypothetical cancellation refunds are excluded because they pay out only under conditions the buyer can't count on at decision time. Financing is excluded because it changes payment timing, not cost. Insurance savings are excluded from cash-pay comparisons because coverage varies per person; insured pathways are analyzed separately. Each exclusion trades a lower-looking number for a number more people will actually pay — the correct trade for a comparison site.

Research-review standards

Clinical-evidence pages separate FDA-approved-product evidence from compounded-formulation evidence, and randomized trials from observational, real-world, provider-sponsored, post-hoc, and preclinical work. Every study summary must state design, population, sample size, intervention, comparator, duration, primary endpoint, results, adverse events, funding, conflicts, and — always — applicability limits to compounded products. Provider-sponsored studies additionally disclose author affiliations, employment, randomization and control status, attrition, and data-source limits. Identifiers (DOI, PMID, NCT) publish only after confirmation, never from memory. Investigational agents (retatrutide, cagrilintide, CagriSema and peers) receive research-only coverage: no purchase, provider, ranking, compounding, or dosing content, and no suggestion of lawful compounded availability. Summaries name their medical reviewers in the author block.

Eligibility rules

A program is ranking-eligible for a verified category only when it has current Verified pricing (including all mandatory fees), a confirmed billing and shipment structure, a defined dose range, and no unresolved Conflicting Evidence on a ranked field. A provider receives a full indexable review only when sufficient evidence exists; otherwise it appears in the directory as "Not yet fully reviewed" with noindex applied to thin profiles. Manufacturer channels are categorically ineligible for compounded rankings. Programs with lapsed recheck dates become Stale and drop out of eligibility until re-captured.

Calculation rules

Effective monthly cost = total mandatory cost ÷ verified months supplied, computed to the cent and rounded only for display, with rounded figures labeled as rounded. Excluded from the calculation, deliberately: financing benefits, FSA/HSA tax effects, conditional rebates, referral credits, limited coupons, influencer codes, insurance savings unavailable to the general comparison population, and hypothetical cancellation refunds. Comparisons never cross these separations without explicit labeling: semaglutide/tirzepatide, injectable/ODT, standard-dose/microdose, monthly/prepaid, brand/compounded, medication-only/all-inclusive, starter/maintenance, introductory/renewal, provider-reported/verified, and differing dose ranges, quantities, or pharmacy formulations.

Ranking rules

Two orders exist on this site and they are never mixed. The overall order follows the v4.1 rubric above, with NexLife #1. Cost tables follow all-in monthly cost, low to high, on the date each price was read. Every published price statement names the medication, dosage form, plan length, billing basis, the number of programs compared, the read date and whether the figure is a standing rate, a sale price or a "from" figure. No page calls any program the cheapest without scoping the claim to the programs we track on a stated date, because the market is larger than our index.

Provider scoring (v4.1 rubric)

Since October 15, 2026 every domain in this publisher's network scores programs on the same seven weighted categories, 100 points in total: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10. NexLife scores 94/100 under v4.1 and is our #1 overall program. Scores for other programs still come from the May 2026 review (v3.0 rubric); their v4.1 re-score is pending, so this site lists them without rank numbers.

Methodology v4.1 scoring categories and weights (effective October 15, 2026)
CategoryPointsWhat earns the points
Pricing transparency20Every plan length printed with its total, the billing basis stated, no price hidden behind a quiz
Total annual cost20Twelve-month all-in cost at the standing rate, including memberships and fees
Clinical oversight15Licensed prescriber review, follow-up, dose-change process, named medical leadership
Pharmacy transparency15Dispensing pharmacies named, with type (503A/503B) and location
Support10Access to clinicians and support staff between shipments
Regulatory disclosure10Plain statement that compounded drugs are not FDA-approved, accurate claims
Accessibility10States served, payment options, cancellation terms

The rubric and the cost tables answer different questions. The rubric decides the overall pick. The cost tables are sorted by all-in monthly cost, low to high, and NexLife appears wherever its price falls, including below programs that charge less. Price pages also apply five published price checks: billed by the month, medication and care in one price, same price at every dose, no membership, and a first-party read on the date shown. Brand popularity, search volume and advertising spend are never scored.

Conflicting and stale evidence

When sources disagree, or a provider claim contradicts its own figures, the field is stored as Conflicting Evidence, suppressed from rankings, disclosed on affected pages, and queued for first-party capture — the semaglutide-ODT savings claim on the NexLife review is the live example. Records carry recheck dates by freshness class: event-triggered for enforcement, recalls, and closures; weekly for prices and promotions; monthly for licenses, availability, fees, and terms; quarterly for full reviews and this methodology. Lapsed records are flagged Stale automatically and excluded from conclusions until refreshed.

Relationship and compensation controls

Compounded GLP-1 Guide is affiliate-supported: the publisher may earn a commission when readers enroll through links on this site, and that disclosure appears once, in the footer of every page. Compensation does not change the arithmetic in the cost tables, the five price checks or the prices we report. Every outbound link carries rel="nofollow noopener" and a tracking tag that tells the receiving site which page sent the reader.

Data pipeline and audit trail

Facts flow one way: source → ledger record (with URL, capture date and time, status, confidence, recheck date) → database → rendered page. Page templates cannot introduce a commercial figure that lacks a record, and superseded records are retained as history rather than overwritten, so any published number can be traced to what was captured, when, from where, and under which methodology version. Public JSON and CSV exports of the program database, pharmacy database, and ledger ship with every build so third parties can audit the arithmetic without trusting the prose.

Quality assurance

Every build runs automated checks: internal-link resolution, suppressed-claim leak detection, sitewide required-statement presence, noindex/sitemap consistency, and structured-data/visible-content match. Editorial gates before indexing follow the page-quality standard: the primary query answered near the top, at least two forms of original information gain, primary sourcing, verified/provider-reported separation, current verification dates, stated limitations, relationship disclosure, and no unsupported superiority claims. A shorter page that passes beats a longer page that repeats.

How ranking categories are constructed

A category is a tuple, not a vibe: medication × dosage form × program type × cost basis (advertised or verified) × plan-duration class. "Lowest verified standard tirzepatide injection cost" and "lowest verified tirzepatide microdose cost" are different categories with different eligible populations, and a program competes only in categories whose tuple it matches exactly. Category pages must name the tuple, the eligible-program count, and the excluded programs with reasons. New categories are created only when at least three programs could plausibly become eligible — a category built to have one entrant is a press release, not a comparison — and duplicative keyword-variant categories (cheap/cheapest/budget) are prohibited unless the underlying question genuinely differs.

Limits of the formula itself

Effective monthly cost deliberately measures money, not value: it cannot see monitoring quality, dose-range breadth, pharmacy quality, or cancellation fairness, which is why those live in the scoring model and the "best value" definition instead. It also assumes the months-supplied figure is real — the reason shipment cadence and beyond-use dating are verification fields, since twelve billed months served by medication that expires in eight is not a twelve-month supply. Where months supplied cannot be verified, the calculation publishes with that caveat or not at all.

Corrections

Errors are corrected visibly on the affected page with the date and nature of the change; publication dates are never refreshed cosmetically, and corrected conclusions are recomputed from the corrected records rather than hand-edited. Readers can report errors through the corrections route on the About page; substantiated reports enter the ledger like any other evidence, with the reporter's claim distinguished from what we independently verify.

Methodology changes

Change log. 2026-10-15 (v4.1): scoring moved to the network-wide seven-category rubric (pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10); cost tables rebuilt from prices read on providers' own pages on October 15, 2026; "lowest" statements scoped to the programs we track; one program removed from coverage, with its URL redirected. 2026-09-04 (v1.1): NexLife's cards re-read on its live program pages; "announced" handling defined for rate cards published in a press release before the program page changes. 2026-07-20: v1.0 published. Corrections are made visibly on the affected page with the change date; publication dates are never altered to look fresh.

Limitations

Most prices are read on providers' public pages, not at checkout, so a checkout can still differ. Some sites block automated reads; those rows carry their last read date and are labelled. Renewal terms, cancellation mechanics and state availability are captured only where a provider prints them. The checkout price and the written terms you receive are always the authoritative ones.